Dr. Julie R. Gralow Discusses Findings from the RxPONDER Study Released at SABCS 2020

A groundbreaking, BCRF-supported phase III clinical trial, RxPONDER, has just demonstrated that some women with a common type of breast cancer can forgo chemotherapy and be successfully treated with hormone therapy alone. The results have far-reaching implications. We asked BCRF investigator and RxPONDER co-author Dr. Julie R. Gralow to break down what patients need to know and what’s to come from this ongoing study.


Leave a Reply

Your email address will not be published.